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Abstract
Background: The Hospital Anxiety and Depression Scale (HADS) is a widely used instrument to
measure psychological morbidity in cancer patients. This study aimed to translate and test the
reliability and validity of the Iranian version of the HADS.
Methods: The English language version of the HADS was translated into Persian (Iranian language)
and was used in this study. The questionnaire was administered to a consecutive sample of 167
breast cancer patients and statistical analysis was performed to test the reliability and validity of the
HADS.
Results: In general the Iranian version of the HADS was found to be acceptable to almost all
patients (99%). Cronbach's alpha coefficient (to test reliability) has been found to be 0.78 for the
HADS anxiety sub-scale and 0.86 for the HADS depression sub-scale. Validity as performed using
known groups comparison analysis showed satisfactory results. Both anxiety and depression sub-
scales discriminated well between sub-groups of patients differing in clinical status as defined by
their disease stage.
Conclusion: This preliminary validation study of the Iranian version of the HADS proved that it
is an acceptable, a reliable and valid measure of psychological distress among cancer patients.
Background
The Hospital Anxiety and Depression Scale (HADS) is a
brief and widely used instrument to measure psychologi-
cal distress in cancer patients and it is available in many
languages for example French, German, Dutch, Italian,
Spanish, Chinese, and Arabic. It has been shown that the
HADS gives clinically meaningful results as a psychologi-
cal screening tool, in clinical group comparisons and in
studies with several aspects of disease and quality of life.
It is sensitive to change both during the course of disease
and in response to medical and psychological interven-
tions [1]. A recent review of the literature on the validity
of the HADS clearly indicates that it is a well-performed
questionnaire in assessing the symptom severity and case-
ness of anxiety disorders and depression in both somatic,
psychiatric and primary care patients and even in the gen-
eral population. The HADS is a popular instrument
among researchers from different nations and it is esti-
mated that since 1996 to 2002 the number of HADS pa-
pers' that have been published has increased almost
fourfold [2].
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The aim of this study was to translate the HADS to Persian
(Iranian language), validate and use the questionnaire in
studies of quality of life in cancer patients in Iran. Current-
ly there is no such questionnaire available in Iran.
Methods
Translation
The 'forward-backward' procedure was applied to trans-
late the HADS from English into Persian (Iranian lan-
guage). Two general practitioners translated the
questionnaire into Persian and these were backward trans-
lated into English by a health professional and a profes-
sional translator. Then, a provisional version of the
Iranian questionnaire was provided. There were some
problematic terms such as 'wound up', 'butterflies in the
stomach' and 'slowed down' which were culturally adapt-
ed and after a consensus by all authors the final version
was developed.
Patients, data collection and statistical analysis
The final draft of the Iranian version was administered to
a sample of newly diagnosed breast cancer patients at-
tending the breast clinic of a large teaching hospital in Te-
hran, Iran. There were no restrictions on patient selection
with regard to histologic type of breast cancer, age or other
characteristics. A trained female nurse during one com-
plete calendar year collected the data in face-to-face inter-
views. The study design and the method of data collection
are fully explained elsewhere [3]. However, to test reliabil-
ity the internal consistency of the questionnaire was meas-
ured using Cronbach's alpha coefficient and alpha equal
to or greater than 0.70 was considered satisfactory. Valid-
ity of the instrument was performed using the known-
groups comparison and convergent analysis [4]. Known
groups comparison analysis was examined to test how
well the questionnaire discriminates between sub-groups
of patients who differed in clinical status as defined by
Table 1: The characteristics of the breast cancer patients and their scores on the HADS (n = 167)
No. %
Age groups
24–29 14 8
30–39 39 24
40–49 47 28
50–59 31 18
60–69 25 15
≥ 70 11 7
Mean (SD) 47.2 (13.5)
Range 24–81
Educational status
Illiterate 38 23
Primary 78 46
Secondary 33 20
College/university 18 11
Marital status
Single 15 9
Married 117 69
Divorced/widowed 36 22
Disease stage
Local 29 17
Loco-regional 76 45
Metastatic 62 38
Anxiety score
Normal (0–7) 45 27
Borderline (8–10) 43 26
Caseness (11–21) 94 47
Mean (SD) 10.6 (4.1)
Range 1–20
Depression score
Normal (0–7) 102 61
Borderline (8–10) 35 21
Caseness (11–21) 30 18
Mean (SD) 6.2 (4.5)
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their disease stage. Convergent validity was assessed using
the correlation of each item with its hypothesized scale.
The Pearson product moment statistic (Pearson's correla-
tion coefficient) of 0.40 or above was considered satisfac-
tory. Further analysis was carried out to demonstrate the
extent to which the HADS correlates with two subscales
derived from the validated Iranian version of the Europe-
an Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30)[5]. It
was expected that the anxiety and the depression subscale
would correlate negatively with these measures (emotion-
al functioning and global quality of life subscales). In ad-
dition inter-correlation between anxiety and depression
subscales was calculated using Pearson's correlation
coefficient.
Questionnaires
The HADS contains 14 items and consists of two sub-
scales: anxiety and depression. Each item is rated on a
four-point scale, giving maximum scores of 21 for anxiety
and depression. Scores of 11 or more on either subscale
are considered to be a significant 'case' of psychological
morbidity, while scores of 8–10 represents 'borderline'
and 0–7 'normal' [6]. Emotional functioning and global
quality of life was measured using the EORTC QLQ-C30
subscales. Emotional functioning contains 4 items and
each item is rated on a four-point scale and global quality
of life contains 2 items and each item is rated on a seven-
point scale. A linear transformation was performed to
standardize the row scores. Scores of each subscales range
from 0 to 100 and the higher values indicate a higher (bet-
ter) level of functioning and global quality of life [7]. De-
mographic data were collected using a short questionnaire
at the patients' first clinic visit and included recording of
age, educational level, and marital status. Disease stage
was extracted from case records.
Results
The characteristics of the breast cancer patients and their
scores on the HADS are shown in Table 1. The mean age
was 47.2 (SD = 13.5) years, most were married (68%),
and had completed primary or secondary education
(66%), and had loco-regional disease (45%). Almost all
patients (99%) found the Iranian version of the HADS ac-
ceptable. The mean anxiety score was 10.6 (SD = 4.1)
whereas this for depression was 6.2 (SD = 4.5).
The internal consistency of the HADS as measured by the
Cronbach's alpha coefficient has been found to be 0.78
for the anxiety subscale and 0.86 for the depression sub-
scale indicating a satisfactory reliability.
Validity of the HADS was examined using the known
groups comparison and convergent analysis. The HADS
well discriminated between sub-groups of patients as de-
fined by their disease stage indicating that anxiety and de-
pression scores were significantly higher in patients with
advanced disease (P < 0.0001 on both subscales). The re-
sults are shown in Table 2. Convergent validity was as-
sessed using the correlation of each item with its
hypothesized scale and the results showed that the Pear-
son's correlation coefficient varied from the 0.47 to 0.83
for anxiety subscale and from 0.48 to 0.86 for depression
subscale, and all were statistically significant (P < 0.0001).
However, item 7 (I can sit at ease and feel relaxed) and
item 11 (I feel restless if I have to be on the move) showed
a weaker correlation with anxiety score (r = 0.47 and 0.50
respectively) and item 10 (I have lost interest in my ap-
pearance) showed a weaker correlation with depression
score (r = 0.48). Furthermore, when the correlation be-
tween the HADS subscales and emotional functioning
and global quality of life (subscales of the EORTC QLQ-
C30) was investigated, as expected a significant negative
correlation emerged. In addition there was a significant
inter-correlation between anxiety and depression sub-
scales as calculated by Pearson's correlation coefficient (r
= 0.72, P < 0.0001). The results are shown in Table 3.
Discussion
This was a validation study of one of the most widely used
instruments to measure anxiety and depression in cancer
patients. The Iranian version of the HADS proved to be ac-
ceptable to patients and it is worth noting that the ques-
tionnaire was administered by a trained nurse in face-to-
Table 2: Breast cancer patients' scores on the HADS anxiety and depression subscales by disease stage (n = 167)
Anxiety score Depression score
Mean (SD) Mean (SD)
Disease stage
Local 7.1 (3.7) 3.4 (3.6)
Loco-regional 10.4 (3.9) 6.2 (4.6)
Metastatic 12.5 (3.3) 7.6 (4.1)
Test of significance* F = 21.5, P < 0.0001 F = 9.5, P < 0.0001
* One-way analysis of variance.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/14
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face interviews, although the original questionnaire is a
self-rating instrument. This was due to the fact that there
were a relatively considerable proportion of illiterate pa-
tients in the study. It is argued that face-to-face interviews
may lead to social desirability bias particularly in sensitive
areas such as assessment of mental health [8]. We do not
know mode of administration through interviews how
much affected the results. However, patients indicated
that some questions were difficult to answer, especially
items 10 and 11. Perhaps this was the reason why a weak-
er correlation was found for these items with their corre-
sponding subscale. It seems that weaker correlation of
items 10 and 11 would also be due to some problems of
translation that might not be reached cross-cultural com-
parability with the original version of the questionnaire.
Similar to most studies reliability of the Iranian version of
the HADS as measured by the internal consistency of the
anxiety and the depression subscales was found to be sat-
isfactory. However, there was a strong correlation between
anxiety and depression subscales. One may argue that this
is evidence to suggest that the instrument is a general
measure of distress rather than a measure of anxiety and
depression. In other words it is possible to suggest that be-
cause of the high correlation between the two HADS sub-
scales it can be used as an unidimensional scale with a
global score for the whole instrument (Table 3). A recent
study in breast cancer patients concluded that the total
score of the HADS is a valid measure of emotional distress
and it can be used as a screening questionnaire for
psychiatric disorders. The same study indicated that the
use of the two subscales as a 'case identifiers' or as an out-
come measure should be considered with caution [9]. In
contrast, apart from findings from several studies that
showed the HADS is a two-factor instrument [10], it has
been suggested that inter-correlation between the anxiety
and the depression subscales is not surprising since this is
mainly due to a real coincidence of anxious and depressed
symptoms and only to a lesser extent to inadequacies of
the instrument [1].
The known groups comparison analysis indicated that the
Iranian version of the HADS is a valid instrument for
measuring anxiety and depression in breast cancer pa-
tients since the instrument was able to discriminate be-
tween patients who were clinically different. However, the
striking finding from this preliminary validation study
was that Iranian women with breast cancer showed a
higher level of anxiety and a relatively lower level of de-
pression. This may reflect the fact that the cut-off score
would be different in Iranian cancer patients so further in-
vestigation might be necessary. Indeed the sensitivity
analysis using an objective criteria or a gold standard test
is needed to answer this question. Unfortunately the
present study was limited in this respect.
As far as assessment of anxiety and depression in breast
cancer patients is concerned studies have shown that the
Table 3: Correlation of HADS items with its hypothesized subscales, overall HADS; and HADS subscales and overall HADS with 
emotional functioning and global quality of life scores
HADS-A (anxiety subscale) HADS-D (depression subscale) HADS (Overall)
Item number/Anxiety (HADS-A) 1 0.72 0.92
1/I feel tense or wound up 0.77 0.65 0.76
3/I get a sort of frightened feeling as if something 
awful is about to happen
0.67 0.51 0.63
5/Worrying thought go through my mind 0.83 0.72 0.83
7/I can sit at ease and feel relaxed 0.47 0.14 0.33
9/I get a sort of frightened feeling like 'butterflies' in 
the stomach
0.76 0.62 0.74
11/I feel restless as if I have to be on the move 0.50 0.14 0.33
13/I get sudden feeling of panic 0.63 0.58 0.65
Item number/Depression (HADS-D) 0.72 1
2/I still enjoy the things I used to enjoy 0.60 0.83 0.78
4/I can laugh and see the funny side of things 0.60 0.84 0.78
6/I feel cheerful 0.65 0.77 0.76
8/I feel as if I am slowed down 0.44 0.58 0.55
10/I have lost interest in my appearance 0.31 0.48 0.43
12/I look forward with enjoyment to things 0.63 0.86 0.81
14/I can enjoy a good book or TV program 0.47 0.79 0.69
Emotional functioning -0.67 -0.63 -0.70
Global quality of life -0.68 -0.75 -0.77
* Pearson's correlation coefficient and all significant at the 0.01 level (P < 0.0001).Publish with BioMed Central    and   every 
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HADS may result in under estimation of psychiatric mor-
bidity among women with early stage breast cancer and
therefore its utility for screening purposes in early stage
breast cancer patients is limited [11,12]. In contrast, most
of the exiting literature suggests that the HADS is a suita-
ble instrument for measuring anxiety and depression in
breast cancer patients [13,14].
The HADS anxiety and depression scores showed a nega-
tive but significant correlation with emotional function-
ing and global quality of life as was expected. This means
that those who were more anxious or depressed showed
lower levels of emotional functioning and global quality
of life. Thus this could be regarded as additional evidence
to suggest the HADS is a valid questionnaire. In a few val-
idation studies usually concurrent validity analysis was
applied using the correlation between the HADS and the
Beck's Depression Inventory (BDI), or the General Health
Questionnaire (GHQ), or the State-Trait Anxiety Invento-
ry (SATI) [15–17]. However, since there was no an Iranian
version of these questionnaires we used two subscales
from the validated Iranian version of the EORTC QLQ-
C30.
Conclusion
In summary, the findings from this preliminary validation
study indicates that the Iranian version of the HADS is a
reliable and valid measure of anxiety and depression and
now it can be used in studies of quality of life in cancer pa-
tients. The next step is to use the questionnaire in different
cancer patients or other chronic disease populations.
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